Imatinib’s mechanism of action

The mechanism of action of Imatinib (Imatinib) involves its key characteristics as a targeted therapy drug, which mainly affects cancer cells in the following ways:

1.Targeting abnormal tyrosine kinase activity: The most important role of imatinib is to target abnormally active tyrosine kinases in cancer cells. In a variety of cancers, including chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and cortical kidney cancer (GIST), abnormal tyrosine kinases play key roles. Imatinib specifically interacts with these abnormal kinases and inhibits their activity. Specifically:

InCML, imatinib reduces the abnormal proliferation of white blood cells by inhibiting the kinase activity of the BCR-ABL fusion protein, thereby controlling the development of the disease.

InGIST, imatinib interferes with the proliferation of tumor cells by inhibiting the abnormal activity of KIT tyrosine kinase.

2.Prevent the growth and division of cancer cells: The effect of imatinib causes the inhibition of abnormal signaling pathways in cancer cells, thereby slowing down the growth and division of cancer cells. This helps prevent further spread and growth of the tumor.

3.Reduce the malignancy of leukemia cells: In leukemias such as CML and ALL, imatinib can reduce the malignancy of leukemia cells, thereby transforming the patient's disease from a potentially fatal lesion to a chronic disease that can be managed long-term.

4.Improve quality of life: Compared with traditional chemotherapy drugs, imatinib usually has lower toxic side effects, making it easier for patients to tolerate treatment. This helps improve the patient's quality of life, allowing them to continue with their normal daily activities and work.

Imatinib was introduced as early as2003It was launched in China in 2012. The domestic medical insurance price is about 700yuan, and the specification is 100mg*60. Since medical insurance varies greatly from place to place, please consult your local pharmacy or medical insurance bureau for specific prices. Foreign medicines are divided into original drugs and generic drugs. Original drugs are mainly Turkish original drugs, and the price is relatively high, about 3300 yuan; generic drugs are mainly Indian generic drugs, and the Indian generic drugs specifications 100mg*120 are priced at around a few hundred yuan, which is much cheaper than domestic ones. The ingredients of foreign original drugs and generic drugs are basically the same as those of domestic imatinib.